Replies to post #180862 on Biotech Values

[masterlongevity]

for an ultra rare disease, BMRN can take a drug through all 3 clinical phases for $70M so its a big deal to them.

[biotech jim]

I was surprised at the price tag also. But for the cholesterol market this could be huge. We shall see.